Tysabri for Crohn’s gets FDA advisory review
FDA's Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees will jointly review Biogen Idec/Elan's Tysabri (natalizumab) for moderately to severely active Crohn's disease July 31. Indicated for multiple sclerosis, Tysabri's sNDA includes results of three trials assessing the biologic as both an induction and maintenance therapy. Biogen pulled Tysabri from the market in 2005 after reports of progressive multifocal leukoencephalopathy, and the company is now in the second phase of the drug's relaunch. One of the three reported cases of PML in the Tysabri database was in a Crohn's patient...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”